{"groups":[{"description":"All participants received the same dose level. All patients received pembrolizumab IV over 30 minutes on day 1 of each cycle. Starting on day 7, all patients also received BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients underwent SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeated every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also underwent CT scan and/or PET-CT scan and collection of blood samples throughout the trial.\n\nBiospecimen Collection: blood sample collection\n\nComputed Tomography: CT and/or PET-CT scan\n\nElimusertib: Given PO\n\nPembrolizumab: Given IV\n\nPositron Emission Tomography: PET-CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nStereotactic Body Radiation Therapy: SBRT","id":"FG000","title":"Treatment (Pembrolizumab, BAY 1895344, SBRT)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Note: One (1) patient started pembro but not the study drug and was lost to follow-up completely after the first dose of pembro."}